| |  Online-Ressource |
|---|
| Verfasst von: | Bühler, Lea [VerfasserIn]  |
|---|
| | Maida, Adriano [VerfasserIn] |
|---|
| | Vogl, Elena Sophie [VerfasserIn] |
|---|
| | Georgiadi, Anastasia [VerfasserIn] |
|---|
| | Takacs, Andrea [VerfasserIn] |
|---|
| | Kluth, Oliver [VerfasserIn] |
|---|
| | Schürmann, Annette [VerfasserIn] |
|---|
| | Feuchtinger, Annette [VerfasserIn] |
|---|
| | Toerne, Christine von [VerfasserIn] |
|---|
| | Tsokanos, Foivos-Filippos [VerfasserIn] |
|---|
| | Klepac, Katarina [VerfasserIn] |
|---|
| | Wolff, Gretchen [VerfasserIn] |
|---|
| | Sakurai, Minako [VerfasserIn] |
|---|
| | Üstünel, Bilgen Ekim [VerfasserIn] |
|---|
| | Nawroth, Peter Paul [VerfasserIn] |
|---|
| | Herzig, Stephan [VerfasserIn] |
|---|
| Titel: | Lipocalin 13 enhances insulin secretion but is dispensable for systemic metabolic control |
|---|
| Verf.angabe: | Lea Bühler, Adriano Maida, Elena Sophie Vogl, Anastasia Georgiadi, Andrea Takacs, Oliver Kluth, Annette Schürmann, Annette Feuchtinger, Christine von Toerne, Foivos-Filippos Tsokanos, Katarina Klepac, Gretchen Wolff, Minako Sakurai, Bilgen Ekim Üstünel, Peter Nawroth, Stephan Herzig |
|---|
| E-Jahr: | 2021 |
|---|
| Jahr: | 3 February, 2021 |
|---|
| Umfang: | 19 S. |
|---|
| Fussnoten: | Gesehen am 29.06.2021 |
|---|
| Titel Quelle: | Enthalten in: Life science alliance |
|---|
| Ort Quelle: | Heidelberg : EMBO Press, 2018 |
|---|
| Jahr Quelle: | 2021 |
|---|
| Band/Heft Quelle: | 4(2021), 4 vom: Apr., Artikel-ID 202000898, Seite 1-19 |
|---|
| ISSN Quelle: | 2575-1077 |
|---|
| Abstract: | Members of the lipocalin protein family serve as biomarkers for kidney disease and acute phase inflammatory reactions, and are under preclinical development for the diagnosis and therapy of allergies. However, none of the lipocalin family members has made the step into clinical development, mostly due to their complex biological activity and the lack of in-depth mechanistic knowledge. Here, we show that the hepatokine lipocalin 13 (LCN13) triggers glucose-dependent insulin secretion and cell proliferation of primary mouse islets. However, inhibition of endogenous LCN13 expression in lean mice did not alter glucose and lipid homeostasis. Enhanced hepatic secretion of LCN13 in either diet-induced or genetic obesity led to no discernible impact on systemic glucose and lipid metabolism, neither in preventive nor therapeutic setting. Of note, loss or forced LCN13 hepatic secretion did not trigger any compensatory regulation of related lipocalin family members. Together, these data are in stark contrast to the suggested gluco-regulatory and therapeutic role of LCN13 in obesity, and imply complex regulatory steps in LCN13 biology at the organismic level mitigating its principal insulinotropic effects. |
|---|
| DOI: | doi:10.26508/lsa.202000898 |
|---|
| URL: | Bitte beachten Sie: Dies ist ein Bibliographieeintrag. Ein Volltextzugriff für Mitglieder der Universität besteht hier nur, falls für die entsprechende Zeitschrift/den entsprechenden Sammelband ein Abonnement besteht oder es sich um einen OpenAccess-Titel handelt.
Volltext ; Verlag: https://doi.org/10.26508/lsa.202000898 |
|---|
| | Volltext: https://www.life-science-alliance.org/content/4/4/e202000898 |
|---|
| | DOI: https://doi.org/10.26508/lsa.202000898 |
|---|
| Datenträger: | Online-Ressource |
|---|
| Sprache: | eng |
|---|
| K10plus-PPN: | 1761434497 |
|---|
| Verknüpfungen: | → Zeitschrift |
|---|
Lipocalin 13 enhances insulin secretion but is dispensable for systemic metabolic control / Bühler, Lea [VerfasserIn]; 3 February, 2021 (Online-Ressource)
